Stefano Genovese

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5308192/publications.pdf

Version: 2024-02-01

98 papers	6,013 citations	117625 34 h-index	71685 76 g-index
103 all docs	103 docs citations	103 times ranked	8692 citing authors

#	Article	IF	Citations
1	Alogliptin after Acute Coronary Syndrome in Patients with Type 2 Diabetes. New England Journal of Medicine, 2013, 369, 1327-1335.	27.0	2,261
2	Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes and Endocrinology,the, 2017, 5, 864-876.	11.4	244
3	Cardiovascular safety of sulfonylureas: a metaâ€analysis of randomized clinical trials. Diabetes, Obesity and Metabolism, 2013, 15, 938-953.	4.4	201
4	Islet autoantibody markers in IDDM: risk assessment strategies yielding high sensitivity. Diabetologia, 1995, 38, 816-822.	6.3	163
5	Glucagon-Like Peptide 1 Reduces Endothelial Dysfunction, Inflammation, and Oxidative Stress Induced by Both Hyperglycemia and Hypoglycemia in Type 1 Diabetes. Diabetes Care, 2013, 36, 2346-2350.	8.6	158
6	Distinct cytoplasmic islet cell antibodies with different risks for Type 1 (insulin-dependent) diabetes mellitus. Diabetologia, 1992, 35, 385-388.	6.3	133
7	The Possible Role of Flavonoids in the Prevention of Diabetic Complications. Nutrients, 2016, 8, 310.	4.1	111
8	Age- and glycemia-related miR-126-3p levels in plasma and endothelial cells. Aging, 2014, 6, 771-786.	3.1	105
9	Liraglutide improves metabolic parameters and carotid intima-media thickness in diabetic patients with the metabolic syndrome: an 18-month prospective study. Cardiovascular Diabetology, 2016, 15, 162.	6.8	98
10	Plasma Triglycerides and HDL-C Levels Predict the Development of Diabetic Kidney Disease in Subjects With Type 2 Diabetes: The AMD Annals Initiative. Diabetes Care, 2016, 39, 2278-2287.	8.6	93
11	Clinical implications of oxidative stress and potential role of natural antioxidants in diabetic vascular complications. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 285-292.	2.6	86
12	A unique plasma microRNA profile defines type 2 diabetes progression. PLoS ONE, 2017, 12, e0188980.	2.5	86
13	Association of IA-2 autoantibodies with HLA DR4 phenotypes in IDDM. Diabetologia, 1996, 39, 1223-1226.	6.3	84
14	Type 1 diabetes and cardiovascular disease. Cardiovascular Diabetology, 2013, 12, 156.	6.8	81
15	N-Glycomic Changes in Serum Proteins in Type 2 Diabetes Mellitus Correlate with Complications and with Metabolic Syndrome Parameters. PLoS ONE, 2015, 10, e0119983.	2.5	81
16	Comparison Review of Short-Acting and Long-Acting Glucagon-like Peptide-1 Receptor Agonists. Diabetes Therapy, 2015, 6, 239-256.	2.5	74
17	The 37/40-kilodalton autoantigen in insulin-dependent diabetes mellitus is the putative tyrosine phosphatase IA-2.. Proceedings of the National Academy of Sciences of the United States of America, 1995, 92, 9412-9416.	7.1	71
18	Variability in <scp>HbA1c</scp>, blood pressure, lipid parameters and serum uric acid, and risk of development of chronic kidney disease in type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 1570-1578.	4.4	70

#	Article	IF	Citations
19	Oscillating glucose induces microRNA-185 and impairs an efficient antioxidant response in human endothelial cells. Cardiovascular Diabetology, 2016, 15, 71.	6.8	66
20	Simultaneous GLP-1 and Insulin Administration Acutely Enhances Their Vasodilatory, Antiinflammatory, and Antioxidant Action in Type 2 Diabetes. Diabetes Care, 2014, 37, 1938-1943.	8.6	64
21	Vitamin C Further Improves the Protective Effect of Glucagon-Like Peptide-1 on Acute Hypoglycemia-Induced Oxidative Stress, Inflammation, and Endothelial Dysfunction in Type 1 Diabetes. Diabetes Care, 2013, 36, 4104-4108.	8.6	61
22	The protective effect of the Mediterranean diet on endothelial resistance to GLP-1 in type 2 diabetes: a preliminary report. Cardiovascular Diabetology, 2014, 13, 140.	6.8	58
23	Extracellular microRNAs and endothelial hyperglycaemic memory: a therapeutic opportunity?. Diabetes, Obesity and Metabolism, 2016, 18, 855-867.	4.4	57
24	Centenarians as super-controls to assess the biological relevance of genetic risk factors for common age-related diseases: A proof of principle on type 2 diabetes. Aging, 2013, 5, 373-385.	3.1	57
25	Glucagon and heart in type 2 diabetes: new perspectives. Cardiovascular Diabetology, 2016, 15, 123.	6.8	52
26	Atherogenicity of postprandial hyperglycemia and lipotoxicity. Reviews in Endocrine and Metabolic Disorders, 2016, 17, 111-116.	5.7	52
27	Kidney dysfunction and related cardiovascular risk factors among patients with type 2 diabetes. Nephrology Dialysis Transplantation, 2014, 29, 657-662.	0.7	49
28	Photodynamic topical antimicrobial therapy for infected foot ulcers in patients with diabetes: a randomized, double-blind, placebo-controlled studyâ€"the D.A.N.T.E (Diabetic ulcer Antimicrobial New) Tj ETQq0 0 0 rgBT /Overlock 10 T	2.5	48
29	Clinical phenotype and Î²-cell autoimmunity in Italian patients with adult-onset diabetes. European Journal of Endocrinology, 2006, 154, 441-447.	3.7	46
30	Short-term high glucose exposure impairs insulin signaling in endothelial cells. Cardiovascular Diabetology, 2015, 14, 114.	6.8	45
31	Self-care, quality of life and clinical outcomes of type 2 diabetes patients: an observational cross-sectional study. Acta Diabetologica, 2017, 54, 1001-1008.	2.5	42
32	Hyperglycemia following recovery from hypoglycemia worsens endothelial damage and thrombosis activation in type 1 diabetes and in healthy controls. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 116-123.	2.6	41
33	Oscillating glucose and constant high glucose induce endoglin expression in endothelial cells: the role of oxidative stress. Acta Diabetologica, 2015, 52, 505-512.	2.5	36
34	Wolfram syndrome 2: a novel CISD2 mutation identified in Italian siblings. Acta Diabetologica, 2015, 52, 175-178.	2.5	34
35	Diabetes Mellitus and Acute Myocardial Infarction: Impact on Short and Long-Term Mortality. Advances in Experimental Medicine and Biology, 2020, 1307, 153-169.	1.6	33
36	Comparison of Capillary Electrophoresis with HPLC for Diagnosis of Factitious Hypoglycemia. Clinical Chemistry, 2000, 46, 1773-1780.	3.2	31

#	Article	IF	Citations
37	Insulinâ€Treated Type 2 Diabetes Is Associated with a Decreased Survival in Heart Failure Patients after Cardiac Resynchronization Therapy. PACE - Pacing and Clinical Electrophysiology, 2008, 31, 1425-1432.	1.2	31
38	Understanding EMPA-REG OUTCOME. Lancet Diabetes and Endocrinology,the, 2015, 3, 929-930.	11.4	29
39	Slow metabolic deterioration towards diabetes in islet cell antibody positive patients with autoimmune polyendocrine disease. Diabetologia, 1994, 37, 365-371.	6.3	28
40	Blood pressure status and the incidence of diabetic kidney disease in patients with hypertension and type 2 diabetes. Journal of Hypertension, 2016, 34, 2090-2098.	0.5	28
41	Focus on migrants with type 2 diabetes mellitus in European Countries. Internal and Emergency Medicine, 2016, 11, 319-326.	2.0	28
42	Novel Considerations on the Antibody/Autoantigen System in Type I (insulin-dependent) Diabetes Mellitus. Annals of Medicine, 1991, 23, 453-461.	3.8	27
43	Contribution of Glutamate Decarboxylase Antibodies to the Reactivity of Islet Cell Cytoplasmic Antibodies. Journal of Autoimmunity, 1994, 7, 497-508.	6.5	27
44	Epidemiology of diabetic kidney disease in adult patients with type 1 diabetes in Italy: The AMDâ€Annals initiative. Diabetes/Metabolism Research and Reviews, 2017, 33, e2873.	4.0	26
45	Glucose-lowering therapy and cardiovascular outcomes in patients with type 2 diabetes mellitus and acute coronary syndrome. Diabetes and Vascular Disease Research, 2019, 16, 399-414.	2.0	26
46	Abnormal DNA Methylation Induced by Hyperglycemia Reduces CXCR4 Gene Expression in CD34+Stem Cells. Journal of the American Heart Association, 2019, 8, e010012.	3.7	26
47	Metabolic syndrome, serum uric acid and renal risk in patients with T2D. PLoS ONE, 2017, 12, e0176058.	2.5	25
48	Selfâ€assembling nanocomposites for protein delivery: Supramolecular interactions between PEGâ€cholane and rhâ€Gâ€CSF. Journal of Controlled Release, 2012, 162, 176-184.	9.9	24
49	Blood Glucose Pattern Management in Diabetes: Creating Order from Disorder. Journal of Diabetes Science and Technology, 2013, 7, 1575-1584.	2.2	24
50	Randomized, double-blind, placebo-controlled trial to evaluate the effect of Helicobacter pylori eradication on glucose homeostasis in type 2 diabetic patients. Nutrition, Metabolism and Cardiovascular Diseases, 2016, 26, 893-898.	2.6	24
51	Predictors of chronic kidney disease in type 1 diabetes: a longitudinal study from the AMD Annals initiative. Scientific Reports, 2017, 7, 3313.	3.3	23
52	Association of kidney disease measures with risk of renal function worsening in patients with hypertension and type 2 diabetes. Journal of Diabetes and Its Complications, 2017, 31, 419-426.	2.3	22
53	A Review of the Long-Term Efficacy, Tolerability, and Safety of Exenatide Once Weekly for Type 2 Diabetes. Advances in Therapy, 2017, 34, 1791-1814.	2.9	21
54	Effects of Vildagliptin/Metformin Therapy on Patient-Reported Outcomes: Work Productivity, Patient Satisfaction, and Resource Utilization. Advances in Therapy, 2013, 30, 152-164.	2.9	20

#	Article	IF	Citations
55	Glycated albumin: correlation to HbA_{1c} and preliminary reference interval evaluation. Clinical Chemistry and Laboratory Medicine, 2017, 55, e31-e33.	2.3	20
56	Use of Liraglutide in the Real World and Impact at 36 Months on Metabolic Control, Weight, Lipid Profile, Blood Pressure, Heart Rate, and Renal Function. Clinical Therapeutics, 2017, 39, 159-169.	2.5	19
57	Long-Term Effectiveness of Liraglutide for Treatment of Type 2 Diabetes in a Real-Life Setting: A 24-Month, Multicenter, Non-interventional, Retrospective Study. Advances in Therapy, 2018, 35, 243-253.	2.9	19
58	Combined analysis of IDDM-related autoantibodies in healthy schoolchildren. Lancet, The, 1994, 344, 756.	13.7	18
59	Vitamin C further improves the protective effect of GLP-1 on the ischemia-reperfusion-like effect induced by hyperglycemia post-hypoglycemia in type 1 diabetes. Cardiovascular Diabetology, 2013, 12, 97.	6.8	17
60	Effect of Pioglitazone Versus Metformin on Cardiovascular Risk Markers in Type 2 Diabetes. Advances in Therapy, 2013, 30, 190-202.	2.9	17
61	A rare genetic variant of BPIFB4 predisposes to high blood pressure via impairment of nitric oxide signaling. Scientific Reports, 2017, 7, 9706.	3.3	17
62	Heterogeneous IgG Subclass Distribution of Islet Cell Antibodies. Journal of Autoimmunity, 1994, 7, 45-53.	6.5	15
63	Enzymatic mono-pegylation of glucagon-like peptide 1 towards long lasting treatment of type 2 diabetes. Results in Pharma Sciences, 2012, 2, 58-65.	4.2	15
64	Evidences of +896 A/G TLR4 Polymorphism as an Indicative of Prevalence of Complications in T2DM Patients. Mediators of Inflammation, 2014, 2014, 1-8.	3.0	15
65	Reduced Cardio-Renal Function Accounts for Most of the In-Hospital Morbidity and Mortality Risk Among Patients With Type 2 Diabetes Undergoing Primary Percutaneous Coronary Intervention for ST-Segment Elevation Myocardial Infarction. Diabetes Care, 2019, 42, 1305-1311.	8.6	15
66	Prognostic impact of admission high-sensitivity C-reactive protein in acute myocardial infarction patients with and without diabetes mellitus. Cardiovascular Diabetology, 2020, 19, 183.	6.8	14
67	Circulating MicroRNA-15a Associates With Retinal Damage in Patients With Early Stage Type 2 Diabetes. Frontiers in Endocrinology, 2020, 11, 254.	3.5	14
68	When Good Guys Turn Bad: Bone Marrowâ€™s and Hematopoietic Stem Cellsâ€™ Role in the Pathobiology of Diabetic Complications. International Journal of Molecular Sciences, 2020, 21, 3864.	4.1	14
69	Improved Glucose Profile in Patients With Type 2 Diabetes With a New, High-Protein, Diabetes-Specific Tube Feed During 4 Hours of Continuous Feeding. Journal of Parenteral and Enteral Nutrition, 2017, 41, 968-975.	2.6	12
70	A donor splice site mutation in CISD2 generates multiple truncated, non-functional isoforms in Wolfram syndrome type 2 patients. BMC Medical Genetics, 2017, 18, 147.	2.1	12
71	GLP-1 reduces metalloproteinase-9 induced by both hyperglycemia and hypoglycemia in type 1 diabetes. The possible role of oxidative stress. Therapeutics and Clinical Risk Management, 2015, 11, 901.	2.0	11
72	The pivotal role of high glucose-induced overexpression of PKCÎ² in the appearance of glucagon-like peptide-1 resistance in endothelial cells. Endocrine, 2016, 54, 396-410.	2.3	10

#	Article	IF	Citations
73	Is there a relationship between factor V Leiden and type 2 diabetes?. Journal of Translational Medicine, 2009, 7, 52.	4.4	9
74	GLP-1 reduces metalloproteinase-14 and soluble endoglin induced by both hyperglycemia and hypoglycemia in type 1 diabetes. Endocrine, 2015, 50, 508-511.	2.3	9
75	Portrait of women with type 1 or type 2 diabetes of childbearing age attending diabetes clinics in Italy: the AMD-Annals initiative. Acta Diabetologica, 2018, 55, 193-199.	2.5	9
76	Renal function impairment predicts mortality in patients with chronic heart failure treated with resynchronization therapy. Cardiology Journal, 2015, 22, 459-466.	1.2	9
77	The simultaneous control of hyperglycemia and GLP-1 infusion normalize endothelial function in type 1 diabetes. Diabetes Research and Clinical Practice, 2016, 114, 64-68.	2.8	8
78	Prevalence and management of diabetes in immigrants resident in the Lombardy Region: the importance of ethnicity and duration of stay. Acta Diabetologica, 2018, 55, 355-362.	2.5	8
79	Algorithms for personalized therapy of type 2 diabetes: results of a web-based international survey. BMJ Open Diabetes Research and Care, 2015, 3, e000109.	2.8	7
80	Lispro insulin in people with non-alcoholic liver cirrhosis and type 2 diabetes mellitus. Diabetes Research and Clinical Practice, 2016, 113, 179-186.	2.8	7
81	Liraglutide preserves CD34+ stem cells from dysfunction Induced by high glucose exposure. Cardiovascular Diabetology, 2022, 21, 51.	6.8	7
82	Setting the hemoglobin A1c target in type 2 diabetes: a priori, a posteriori, or neither?. Endocrine, 2015, 50, 56-60.	2.3	6
83	Cost-consequence analysis of sitagliptin versus sulfonylureas as add-on therapy for the treatment of diabetic patients in Italy. ClinicoEconomics and Outcomes Research, 2017, Volume 9, 699-710.	1.9	6
84	Generation of Human-Induced Pluripotent Stem Cells from Wolfram Syndrome Type 2 Patients Bearing the c.103â€‰+â€‰1G>A CISD2 Mutation for Disease Modeling. Stem Cells and Development, 2018, 27, 287-295.	2.1	6
85	Changing the approach to type 2 diabetes treatment: A comparison of glucagonâ€like peptideâ€1 receptor agonists and sulphonylureas across the continuum of care. Diabetes/Metabolism Research and Reviews, 2021, 37, e3434.	4.0	5
86	Low interleukin-2 receptor levels in serum of patients with insulin-dependent diabetes. The Clinical Investigator, 1994, 72, 494-8.	0.6	4
87	Nutritional imbalances linking cellular senescence and type 2 diabetes mellitus. Current Opinion in Clinical Nutrition and Metabolic Care, 2014, 17, 338-342.	2.5	4
88	HLA-DQ screening for risk assessment of insulin dependent diabetes in northern Italy. Acta Diabetologica, 1995, 32, 137-142.	2.5	3
89	The evolving frontier of diabetes therapy: The renaissance of glycemology. Diabetes Research and Clinical Practice, 2016, 118, 168-171.	2.8	3
90	Cardiovascular guidelines: separate career may help attenuate controversy. Cardiovascular Diabetology, 2014, 13, 66.	6.8	2

#	Article	IF	Citations
91	Comment on Ferrannini et al. Diabetes Care 2016;39:1108â€“1114. Comment on Mudaliar et al. Diabetes Care 2016;39:1115â€“1122. Diabetes Care, 2016, 39, e195-e195.	8.6	1
92	Patient-reported outcomes in elderly patients with type 2 diabetes mellitus treated with dual oral therapy: a multicenter, observational study from Italy. Current Medical Research and Opinion, 2020, 36, 555-562.	1.9	1
93	Can the in-hospital mortality gap between STEMI patients with and without diabetes mellitus be reduced? The cardio-renal hypothesis. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1516-1520.	2.6	1
94	Pioglitazone Randomised Italian Study on Metabolic Syndrome (PRISMA): effect of pioglitazone with metformin on HDL-C levels in Type 2 diabetic patients. Journal of Endocrinological Investigation, 2013, 36, 606-16.	3.3	1
95	Vitamin C Further Improves the Protective Effect of Glucagon-Like Peptide-1 on Acute Hypoglycemia-Induced Oxidative Stress, Inflammation, and Endothelial Dysfunction in Type 1 Diabetes. Diabetes Care 2013;36:4104â€“4108. Diabetes Care, 2014, 37, 2063.1-2063.	8.6	0
96	Economic Burden of Type 2 Diabetes Mellitus Treatment Strategies: A Cost Consequence Analysis of Sitagliptin vs Sulfonylureas in Lombardy Region. Value in Health, 2015, 18, A606.	0.3	0
97	Comment on Giacco et al. GLP-1 Cleavage Product Reverses Persistent ROS Generation After Transient Hyperglycemia by Disrupting an ROS-Generating Feedback Loop. Diabetes 2015;64:3273â€“3284. Diabetes, 2016, 65, e5-e5.	0.6	0
98	Preclinical characterization of eleven new Cys-PEGylated hGH mutants. European Journal of Molecular and Clinical Medicine, 2017, 2, 147.	0.1	0